Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Luteoloside Inhibits the Progression and Enhances Chemosensitivity to Cytarabine in Acute Myeloid Leukemia via β-Catenin/c-Myc Axis.

Phytotherapy research : PTR·2026
Same author

Asymmetric Total Synthesis and Antihypoxic Neuroinflammatory Evaluation of Notopterol, Notoptol, and Their Natural Analogues.

Organic letters·2026
Same author

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Cancer communications (London, England)·2026
Same author

CD244 modulates bone marrow infiltrating CD8<sup>+</sup> T cells and serves as a prognostic and immunotherapeutic target in acute myeloid leukemia.

Leukemia research·2026
Same author

DNA-contact mutant p53 displaces BRCA2 from chromatin and drives R-loop-associated genome instability.

Genome biology·2026
Same author

Sleep Traits and Cognitive Function: A Prospective Cohort Study With Exploration of Inflammatory Biomarkers.

Brain and behavior·2026

Related Experiment Video

Updated: Aug 23, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Boron Neutron Capture Therapy: Clinical Application and Research Progress.

Xiang Cheng1, Fanfan Li1, Lizhen Liang2

  • 1Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China.

Current Oncology (Toronto, Ont.)
|October 27, 2022
PubMed
Summary

Boron neutron capture therapy (BNCT) selectively targets tumors using boron-10. This review examines clinical studies of second-generation boron delivery agents to improve cancer treatment outcomes.

Keywords:
boron delivery agentsboron neutron capture therapy (BNCT)radiationthermal neutrontumor

More Related Videos

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

11.2K
Neutron Radiography and Computed Tomography of Biological Systems at the Oak Ridge National Laboratory's High Flux Isotope Reactor
10:24

Neutron Radiography and Computed Tomography of Biological Systems at the Oak Ridge National Laboratory's High Flux Isotope Reactor

Published on: May 7, 2021

2.4K

Related Experiment Videos

Last Updated: Aug 23, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

11.2K
Neutron Radiography and Computed Tomography of Biological Systems at the Oak Ridge National Laboratory's High Flux Isotope Reactor
10:24

Neutron Radiography and Computed Tomography of Biological Systems at the Oak Ridge National Laboratory's High Flux Isotope Reactor

Published on: May 7, 2021

2.4K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • Boron neutron capture therapy (BNCT) is a binary cancer treatment modality.
  • BNCT utilizes boron-10 (10B) and neutron irradiation to generate high-energy particles for tumor cell destruction.
  • Selective delivery of 10B to tumor cells over normal tissues is crucial for BNCT efficacy.

Purpose of the Study:

  • To review and collate clinical studies on second-generation boron delivery agents for BNCT.
  • To analyze the impact of drug combinations, administration methods, and multimodal treatments on patient survival.
  • To identify critical challenges for the development of next-generation boron delivery agents.

Main Methods:

  • Systematic review of clinical studies involving second-generation boron delivery agents.
  • Analysis of treatment parameters including drug combinations and administration routes.
  • Evaluation of patient survival data in relation to treatment strategies.

Main Results:

  • BNCT has demonstrated efficacy in treating head and neck cancers, malignant meningiomas, melanomas, and hepatocellular carcinomas.
  • Clinical outcomes are significantly influenced by the choice of boron delivery agents, drug combinations, and administration protocols.
  • Over 2000 BNCT cases have been reported globally, confirming its therapeutic potential.

Conclusions:

  • Second-generation boron delivery agents show promise in enhancing BNCT efficacy.
  • Optimizing drug combinations, administration, and integrating BNCT with other therapies are key to improving patient survival.
  • Addressing current challenges is essential for advancing the development and application of future boron delivery agents in BNCT.